Cover Image

Tocilizumab (Actemra)

Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA). This article provides an overview...

Full description

Saved in:

Bibliographic Details
Main Authors:	Martin Sheppard (Author), Faidra Laskou (Author), Philip P. Stapleton (Author), Shahryar Hadavi (Author), Bhaskar Dasgupta (Author)
Format:	Book
Published:	Taylor & Francis Group, 2017-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects
by: Guoying Cao, et al.
Published: (2023)

Pharmacoeconomic analysis of Actemra<sup>®</sup> in first-line treatment of rheumatoid arthritis in the modes of combination and monotherapy
by: S. K. Zyryanov, et al.
Published: (2018)

Associations of osteoporosis and sarcopenia with frailty and multimorbidity among participants of the Hertfordshire Cohort Study
by: Faidra Laskou, et al.
Published: (2022)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
by: Rania M. Sarhan, et al.
Published: (2022)

Keratoconjunctivitis associated with atopic dermatitis treated with tocilizumab
by: Celia Raga Jiménez, et al.
Published: (2018)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
by: Shetty A, et al.
Published: (2014)

Tocilizumab-Induced Erythema Annulare Centrifugum
by: Ana Luísa João, et al.
Published: (2022)

Tocilizumab in the Treatment of Juvenile Rheumatoid Arthritis
by: V.V. Berejniy, et al.
Published: (2015)

Tocilizumab for the Treatment of Mevalonate Kinase Deficiency
by: Nadia K. Rafiq, et al.
Published: (2018)

A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects
by: Hongjie Qian, et al.
Published: (2023)

Urticarial drug eruption following tocilizumab administration
by: Hikaru Nanamori, et al.
Published: (2022)

Tocilizumab prescribing criteria for COVID-19 patients
by: Ayman M. Al-Qaaneh, et al.
Published: (2021)

Tocilizumab for faster and safer remission of Takayasu's arteritis
by: Hua Liao, et al.
Published: (2022)

Tocilizumab and COVID-19: Timing of Administration and Efficacy
by: Emna Abidi, et al.
Published: (2022)

Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors
by: V. I. Petrov, et al.
Published: (2022)

Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
by: Alexandra A. Taube, et al.
Published: (2020)

Tocilizumab for refractory morphea in adults: A case series
by: Sarah Lonowski, MD, MBA, et al.
Published: (2022)

The first report of Tocilizumab for Darier disease with summer exacerbations
by: Lele Chen, et al.
Published: (2024)

Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis
by: Sakkas LI
Published: (2016)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
by: Mahamid M, et al.
Published: (2011)

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
by: Yilmaz S, et al.
Published: (2013)

Experience of the Tocilizumab Application in Systemic Onset Juvenile Arthritis
by: A. V. Krasnopol'skaja, et al.
Published: (2015)

Pharmacoeconomic analysis of subdermal tocilizumab in patients with rheumatoid arthritis
by: S. K. Zyryanov, et al.
Published: (2018)

Rapid desensitisation to tocilizumab in systemic idiopathic juvenile arthritis
by: Rosalaura Villarreal González, et al.
Published: (2021)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
by: Livermore P, et al.
Published: (2008)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
by: Hofer M, et al.
Published: (2011)

Tocilizumab-Induced Sweet Syndrome in a Patient With Polymyalgia Rheumatica
by: Federica Filippi, et al.
Published: (2019)

Takayasu arteritis of atypical presentation. Tocilizumab as an alternative therapeutic option
by: Zaira Cubiles Arillo, et al.
Published: (2019)

Prevention of bleomycin-induced pulmonary fibrosis by vaccination with the Tocilizumab mimotope
by: Jin Guo, et al.
Published: (2024)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
by: Linda L Hushaw, et al.
Published: (2010)

Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19
by: Maria Laura Belladonna, et al.
Published: (2020)

Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case
by: E. I. Alekseeva, et al.
Published: (2016)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
by: Joly J, et al.
Published: (2011)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
by: Yokota Shumpei, et al.
Published: (2011)

Tocilizumab for refractory Castleman's disease with paraneoplastic pemphigus and Behçet's disease
by: Vargas Ana, et al.
Published: (2012)

Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab
by: Koné-Paut I, et al.
Published: (2011)

Psoriasiform Dermatitis Developing during Treatment of Juvenile Idiopathic Arthritis with Tocilizumab
by: Yoshiaki Matsushima, et al.
Published: (2019)

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
by: Abeer Al-Baadani, et al.
Published: (2021)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
by: Biggioggero M, et al.
Published: (2018)

Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
by: Luis Sarabia De Ardanaz, et al.
Published: (2021)